NCT01898117.

Study name	Biomarker Discovery Randomized Phase IIb Trial With Carboplatin‐cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First‐line Treatment in Advanced Triple Negative Breast Cancer.
Methods	Randomised phase IIb trial.
Participants	Participants with advanced triple‐negative breast cancer.
Interventions	Carboplatin‐cyclophosphamide vs paclitaxel with or without bevacizumab.
Outcomes	PFS. OS. Toxicity.
Starting date	July 2013. Estimated primary completion date: December 2019.
Contact information	Sabine C Linn, Prof, MD, email; s.linn@nki.nl.
Notes